|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
1,220,000,000 |
Market
Cap: |
14.41(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$8.77 - $13.53 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 979 |
Guru Rank Value : 0 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Viatris is a global healthcare company. Co.'s portfolio comprises more than 1,400 approved molecules across a range of key therapeutic areas. Co. has four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Key products sold by the Developed Markets segment include Lyrica®, Lipitor®, Creon®, Influvac®, Wixela Inhub, and the EpiPen® Auto-Injector. Key products within the Greater China segment include Lipitor®, Norvasc®, and Viagra®. Key products within the JANZ segment include AMITIZA®, Lipacreon®, Lyrica®, Norvasc®, and Effexor®. Among Co.'s products sold in the Emerging Markets segment are Lipitor®, Lyrica®, Norvasc®, Celebrex®, and anti-retrovirals.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
323,885 |
346,822 |
346,822 |
376,566 |
Total Sell Value |
$3,944,486 |
$4,172,428 |
$4,172,428 |
$4,507,109 |
Total People Sold |
5 |
5 |
5 |
7 |
Total Sell Transactions |
6 |
9 |
9 |
14 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Parrish Mark W |
Director |
|
2022-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
166 |
82,250 |
|
- |
|
Cornwell W Don |
Director |
|
2022-03-15 |
4 |
B |
$9.90 |
$26,721 |
D/D |
2,700 |
22,031 |
2.39 |
-2% |
|
Goettler Michael |
Chief Executive Officer |
|
2022-03-15 |
4 |
B |
$9.87 |
$496,773 |
D/D |
50,352 |
136,796 |
2.81 |
-2% |
|
Coury Robert J |
Executive Chairman |
|
2022-03-11 |
4 |
S |
$10.07 |
$2,518,275 |
I/I |
(250,000) |
0 |
|
1% |
|
Coury Robert J |
Executive Chairman |
|
2022-03-09 |
4 |
S |
$10.28 |
$2,569,050 |
I/I |
(250,000) |
250,000 |
|
2% |
|
Lyons Dillon Joellen |
Director |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,331 |
39,380 |
|
- |
|
Taddese Menassie |
See Remarks |
|
2022-03-02 |
4 |
D |
$10.48 |
$32,142 |
D/D |
(3,067) |
8,767 |
|
- |
|
Taddese Menassie |
See Remarks |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,309 |
8,840 |
|
- |
|
Read Ian C |
Director |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,331 |
14,331 |
|
- |
|
Coury Robert J |
Executive Chairman |
|
2022-03-02 |
4 |
D |
$10.48 |
$536,125 |
D/D |
(51,157) |
1,061,659 |
|
- |
|
Coury Robert J |
Executive Chairman |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
103,179 |
1,062,854 |
|
- |
|
Narula Sanjeev |
Chief Financial Officer |
|
2022-03-02 |
4 |
D |
$10.48 |
$122,480 |
D/D |
(11,687) |
22,378 |
|
- |
|
Narula Sanjeev |
Chief Financial Officer |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,751 |
22,650 |
|
- |
|
Higgins Melina E |
Director |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,331 |
62,902 |
|
- |
|
Cuneo Andrew |
See Remarks |
|
2022-03-02 |
4 |
D |
$10.48 |
$116,978 |
D/D |
(11,162) |
30,977 |
|
- |
|
Cuneo Andrew |
See Remarks |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,524 |
31,056 |
|
- |
|
Cuneo Andrew |
See Remarks |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,018 |
28,993 |
|
- |
|
Kilts James M |
Director |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,331 |
79,236 |
|
- |
|
Korman Harry |
Director |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,331 |
50,472 |
|
- |
|
Campbell Paul |
See Remarks |
|
2022-03-02 |
4 |
GA |
$0.00 |
$0 |
D/D |
1,629 |
69,102 |
|
- |
|
Campbell Paul |
See Remarks |
|
2022-03-02 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,629 |
0 |
|
- |
|
Campbell Paul |
See Remarks |
|
2022-03-02 |
4 |
D |
$10.48 |
$8,866 |
I/I |
(846) |
1,629 |
|
- |
|
Campbell Paul |
See Remarks |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
I/I |
2,475 |
1,637 |
|
- |
|
Campbell Paul |
See Remarks |
|
2022-03-02 |
4 |
D |
$10.48 |
$189,520 |
D/D |
(18,084) |
67,473 |
|
- |
|
Campbell Paul |
See Remarks |
|
2022-03-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,808 |
67,620 |
|
- |
|
221 Records found
|
|
Page 6 of 9 |
|
|